The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

and human epidermal growth factor receptor 2 (HER2/neu)—that targeted medications act upon to reduce tumor growth. Even when initial treatment leads to remission, the chance of triple-negative ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins ... breast cancer is similar to that of HER2-negative breast cancer, but it usually also includes ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...

Triple-negative breast cancer (TNBC) remains one of the most aggressive types of breast cancer. Determined by a lack of three markers, estrogen receptors, progesterone receptors, and HER2/neu protein, ...

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.